Cardiovascular Effects of Nicotine, Chlorisondamine, and Mecamylamine in the Pigeon

Kathryn K. Chadman and James H. Woods
Departments of Pharmacology (K.K.C., J.H.W.) and Psychology (J.H.W.), University of Michigan, Ann Arbor, Michigan

Received July 21, 2003; accepted October 2, 2003

ABSTRACT

Chlorisondamine and mecamylamine are nicotinic antagonists that produce both ganglionic and central blockade. Chlorisondamine, when administered as a large systemic dose, produces a persistent central block, despite being charged. The present study evaluated the cardiovascular effects of chlorisondamine. Shortly after administration, chlorisondamine (0.10, 1, and 10 mg/kg i.m.) lowered blood pressure significantly and decreased heart rate at the low dose (0.1 mg/kg i.m.) and increased heart rate at the high dose (10 mg/kg i.m.). Mecamylamine (1 and 10 mg/kg i.m.) also lowered blood pressure and heart rate. After both antagonists, heart rate returned to baseline values within 90 min and blood pressure within 24 h. Low doses of nicotine (0.01–0.03 mg/kg i.m.) lowered blood pressure but did not affect heart rate. Higher doses (0.10–3.2 mg/kg i.m.) transiently increased blood pressure and heart rate. Subsequent to antagonist administration, nicotine was administered to determine whether either drug blocked the cardiovascular effects of nicotine. Chlorisondamine (0.1, 1, and 10 mg/kg i.m.) administered 30 min before nicotine blocked the increases in blood pressure and heart rate. Only the high dose (10 mg/kg i.m.) of chlorisondamine administered 24 h before nicotine produced a blockade of nicotine’s pressor effect. This block diminished within 3 days. Mecamylamine (1 mg/kg i.m.) antagonized only nicotine’s tachycardic effect. Longer pretreatment with mecamylamine (10 mg/kg, 24 h before nicotine challenge) did not antagonize the cardiovascular effects of nicotine. Thus, chlorisondamine produces a longer lasting blockade of nicotine’s cardiovascular effects than mecamylamine.

Chlorisondamine and mecamylamine are antagonists of nicotinic acetylcholine receptors in the autonomic ganglia. Blockade of ganglionic nicotinic acetylcholine receptors attenuates sympathetic input to arteries, causing vasodilation and a decrease in blood pressure. Ganglionic blocking drugs were used to treat hypertension, but their use was limited by side effects such as dizziness, fatigue, pupil dilation, dryness of mouth, visual impairments, and orthostatic hypotension (Smirk and Hamilton, 1956; Darvill and Bakke, 1957; Anonymous, 1962). The purpose of this study is to evaluate the cardiovascular effects of chlorisondamine to compare its peripheral and central nicotinic blockade in pigeons.

Chlorisondamine is a charged molecule that does not penetrate the blood-brain barrier readily. Therefore, blockade of central nicotinic effects is not apparent until 24 h after administration, whereas autonomic blockade occurs rapidly. A systemic dose of 10 mg/kg chlorisondamine is necessary to achieve persistent central blockade in rats (Clarke, 1984; Decker et al., 1994a,b; el-Bizri and Clarke, 1994; Clarke and Reuben, 1996; Reuben et al., 1998); however, a 10- to 100-fold lower dose will block nicotinic acetylcholine receptors in the autonomic ganglia. The central blockade endures up to 1 week in the pigeon (Chadman and Woods, 2001) and 3 to 12 weeks in rodents (Clarke, 1984; Decker et al., 1994a,b; el-Bizri and Clarke, 1994; Clarke and Reuben, 1996; Reuben et al., 1998).

Blockade of central nicotinic receptors may help in smoking cessation therapy by blocking the positive reinforcing effects of nicotine, thereby dissociating them from the action of smoking. Central blockade of nicotinic receptors by chlorisondamine has been characterized most fully in the rat. An i.p. injection of 10 mg/kg chlorisondamine attenuates the nicotine-induced increases in locomotor activity for up to 5 weeks (Clarke, 1984; Decker et al., 1994a,b) and blocks ex vivo nicotine-induced release of [3H]dopamine (el-Bizri and Clarke, 1994) or [3H]norepinephrine from synaptosomes for up to 12 weeks (Clarke and Reuben, 1996; Reuben et al., 1998). In the pigeon, chlorisondamine (7.5 mg/kg i.m.) antagonizes decreases in rate for food-reinforced pecking caused by nicotine for up 4 days (Chadman and Woods, 2001).

The systemic dose of chlorisondamine necessary for persistent central nicotinic blockade seems to be 10-fold higher than the dose needed for ganglionic blockade. The effects of nicotine are attenuated by chlorisondamine administered 30 min before nicotine, but higher doses administered 24 h before nicotine produced a more persistent blockade.

This study was supported by U.S. Public Health Service Grant T32 DA07267-06 through the University of Michigan Substance Abuse Research Center.

ABBREVIATION: ANOVA, analysis of variance.
Subjects. White Carneaux pigeons, housed individually, were used for these experiments. The pigeons were between 450 and 630 g, housed singly with a 12-h light/dark schedule. The pigeons had food, water, and grit freely available. Studies were performed in accordance with the Guide for the Use and Care of Laboratory Animals as adopted and promulgated by the National Institutes for Health. The experimental protocols were approved by the University of Michigan University Committee for the Use and Care of Animals.

Surgery. The pigeons were hooded and restrained. The area surrounding the brachial artery was anesthetized with lidocaine and swabbed with disinfectant. The brachial artery was exposed and a catheter inserted. The area was then sutured and the catheter plugged.

Cardiovascular Testing. The arterial catheter was connected to a pressure transducer coupled to a Grass polygraph; data were recorded using Polyview software (Astro-Med, Inc., West Warrick, RI). Pigeons were allowed to habituate for 20 min at the beginning of the session. Then a saline intramuscular injection was administered and blood pressure and heart rate recorded for 10 min. After that period, either a ganglionic blocking drug was administered and recorded alone and/or followed by nicotine injections spaced 20 min apart. All injections were administered intramuscularly. The first group of experiments compares the effects of three doses of chlorisondamine (0.1, 1, and 10 mg/kg) and two doses of mecamylamine (1 and 10 mg/kg) for 2 h on blood pressure and heart rate in the pigeon. The next set of experiments evaluates increasing doses of nicotine (0.01–3.2 mg/kg) on blood pressure and heart rate and after pretreatment with chlorisondamine (0.1, 1, or 10 mg/kg); mecamylamine (1 or 10 mg/kg); or vehicle 30 min or 24 h before the nicotine doses to ascertain whether the effects of chlorisondamine on blood pressure and heart rate can be overcome by nicotine.

Data Analysis. Heart rate and blood pressure were averaged over 10 s from each min for each recording. In the groups administered one dose of chlorisondamine or mecamylamine, the baseline blood pressure and heart rate values from each subject were subtracted out and the data presented as change from the saline baseline. A one-way ANOVA with Tukey’s multiple comparison post test was used to compare the groups. The data from the groups pretreated with chlorisondamine or mecamylamine followed by nicotine were divided by the time-matched values from the saline group and presented as percentage of saline. The peak values subsequent to each injection were analyzed comparing the groups using two-way ANOVA with Bonferroni’s post tests.

Materials. Chlorisondamine diiodide was purchased from Tocris Cookson (Ellisville, MO). Mecamylamine, nicotine base, and lidocaine were purchased from Sigma-Aldrich (St. Louis, MO). The drugs were dissolved in sterile water or saline.

Results
The first set of experiments measured the change in heart rate and blood pressure over a several chlorisondamine (0.1–10 mg/kg) and mecamylamine (1–10 mg/kg) doses. A single injection of saline lead to a gradual ~5 mm Hg decrease in blood pressure, from 130 to 125 mm Hg over the course of the recording session (Fig. 1A, change from baseline). Heart rate of pigeons varied around 175 beats per minute over the recording session after a single saline injection (Fig. 1B, change from baseline).

Chlorisondamine and Mecamylamine Treatment. Chlorisondamine (0.10, 1, and 10 mg/kg) lowered blood pressure significantly (p < 0.001) compared with saline (Fig. 1A). The decrease in blood pressure after 0.1 mg/kg chlorisondamine was not as long-lasting as the higher doses and returned close to baseline levels by 75 min. The depressor effect (10–15 mm Hg decrease) of the larger doses of chlorisondamine (1 and 10 mg/kg) had a faster onset and lasted for the remainder of the recording session (2 h); but it returned to baseline values at 24 h (data not shown).

Chlorisondamine caused a biphasic, dose-dependent response in heart rate (Fig. 1B). The lowest dose of chlorisondamine, 0.1 mg/kg, lowered heart rate (p < 0.001), 1 mg/kg had no effect, and 10 mg/kg increased heart rate (p < 0.001). After 0.10 mg/kg chlorisondamine, heart rate lowered rapidly and returned to control group levels within 35 min (Fig. 1B). Chlorisondamine, 10 mg/kg, reached the peak increase in heart rate at 10 min and gradually returned to similar levels as the control group after 75 min (Fig. 1B).

The changes in heart rate did not follow the same time course as the decrease in blood pressure. Chlorisondamine, 0.1 mg/kg, lowered both blood pressure and heart rate, but the higher dose (10 mg/kg) lowered blood pressure and increased heart rate. Chlorisondamine, 1 mg/kg, lowered blood...
pressure within 20 min and maintained its decrease for the entire session but caused no change in heart rate. Chlorisondamine (10 mg/kg) took 30 min to achieve the maximum depressor effect and maintained the decrease for the entire session, whereas the increase in heart rate peaked within 10 min and was gone in 75 min.

Mecamylamine significantly lowered both blood pressure (p < 0.001; Fig. 1C) and heart rate (p < 0.001; Fig. 1D).

**Nicotine.** Nicotine was administered in increasing doses from 0.01 to 3.2 mg/kg at 20-min intervals. Twenty-minute intervals were chosen because nicotine is a fast-acting drug, and this allowed time for blood pressure and heart rate to return to baseline values between injections. As a control, saline injections were administered at the same time intervals. During the repeated saline injections blood pressure gradually decreased by 20 mm Hg (Fig. 2A) with small increases after each injection. This decrease in blood pressure was larger than observed after a single saline injection (Fig. 1A). Heart rate was relatively stable between 175 and 200 beats per minute (Fig. 2B) over the session, which was slightly higher than the heart rate after a single saline injection (Fig. 1B). The peak heart rate and blood pressure after each saline injection did not differ greatly among the saline injections and were used as the 100% baseline (Fig. 2, A and B, insets).

There was no change in blood pressure or heart rate at low doses of nicotine (0.01 and 0.032 mg/kg). As the nicotine dose increased from 0.10 to 3.2 mg/kg, nicotine immediately caused a transient increase in blood pressure and heart rate (Fig. 2, A and B), with the increase reaching a maximum at 0.10 mg/kg nicotine. The increase in blood pressure had a longer duration as the dose increased, but after the highest dose (3.2 mg/kg) there was a fast drop in blood pressure after the peak increase. However, blood pressure did not fall as low as the values from the subjects in the repeated saline injection group.

**Nicotine-Antagonist Interactions: Blood Pressure.** Chlorisondamine (0.10 mg/kg) 30 min before nicotine signif-

---

**Fig. 1.** Effect of saline, chlorisondamine, and mecamylamine on blood pressure (A and C) and heart rate (B and D) in the pigeon. Drug injections were administered at time 0 and recorded for 2 h. Baseline blood pressure and heart rate values were subtracted from each individual pigeon and expressed as change from baseline over time (n = 8, each). Data were analyzed using one-way ANOVA, Tukey’s multiple comparison post test, *, p < 0.05; **, p < 0.01; and ***, p < 0.001.

**Fig. 2.** Nicotine (n = 8–18) was administered in increasing doses and recorded for 20 min after each dose. As a control, saline (n = 7) was injected at the same time intervals as nicotine. The peak blood pressure and heart rate after each saline injection were calculated (insets) and used as the 100% baseline for Figs. 3 and 4.
significantly \( (p < 0.05) \) attenuated the peak pressor effects of nicotine (Fig. 3A). When this dose of chlorisondamine was administered 24 h before the nicotine doses there was no blockade of nicotine-induced increases in blood pressure, and there was a slight, nonsignificant, enhancement of the peak effects of nicotine (Fig. 3A).

The 30-min pretreatment of chlorisondamine (1 mg/kg) significantly \( (p < 0.001) \) antagonized the nicotine-induced increases in blood pressure (Fig. 3B). With 24-h pretreatment of 1 mg/kg chlorisondamine, the pressor effect of the lowest doses of nicotine (0.01–0.032 mg/kg) was enhanced similarly to that observed with 24-h pretreatment with 0.1 mg/kg chlorisondamine (Fig. 3A).

The largest dose of chlorisondamine, 10 mg/kg, significantly \( (p < 0.001) \) antagonized the nicotine-induced increases in blood pressure (Fig. 3B). With 24-h pretreatment of 1 mg/kg chlorisondamine, the pressor effect of the lowest doses of nicotine (0.01–0.032 mg/kg) was enhanced similarly to that observed with 24-h pretreatment with 0.1 mg/kg chlorisondamine.

A 30-min pretreatment of 1 mg/kg mecamylamine did not attenuate the nicotine-induced increases in blood pressure (Fig. 3D). Twenty-four-hour pretreatment with 10 mg/kg mecamylamine did not significantly block nicotine’s pressor effect (Fig. 3D). However, there was a significant \( (p < 0.01) \) difference in the peak blood pressure after nicotine doses between 30-min pretreatment of 1 mg/kg mecamylamine and 24-h pretreatment of 10 mg/kg. The 30-min pretreatment of 1 mg/kg mecamylamine blocked the pressor effect of nicotine, whereas 10 mg/kg mecamylamine at 24 h was similar to the lower doses of chlorisondamine and had a trend toward enhancing the pressor effect of nicotine.

**Nicotine-Antagonist Interactions: Heart Rate.** Chlorisondamine (0.10 mg/kg), regardless of length of pretreatment had no significant effect on nicotine-induced increases in heart rate (Fig. 4A). The 30-min pretreatment of chlorisondamine significantly \( (p < 0.05) \) increased the peak effect of 0.032 mg/kg nicotine only, the opposite of the decrease in heart rate observed after 0.10 mg/kg chlorisondamine alone (Fig. 2B). Chlorisondamine (1 mg/kg) had no significant effect on heart rate (Fig. 2B), nor did it block nicotine-induced tachycardia when administered 30 min or 24 h prior (Fig. 4B). There was no significant effect of 10 mg/kg chlorisondamine to block the tachycardic effect of nicotine at 30 min; however, there was a significant attenuation at 24 h \( (p < 0.05) \) (Fig. 4B) and 3 days \( (p < 0.001) \) (Fig. 4C). Chlorisondamine (10 mg/kg) alone raised heart rate (Fig. 2B) and enhanced the tachycardic effect of the lowest doses of nicotine (0.01 and 0.032 mg/kg), but it did not affect the higher doses of nicotine (Fig. 4C).

Mecamylamine (1 and 10 mg/kg) administered alone lowered heart rate (Fig. 1D). Mecamylamine (1 mg/kg, 30 min) significantly blocked the increases in heart rate caused by nicotine \( (p < 0.001) \), but 10 mg/kg (24 h) did not (Fig. 4D).

**Discussion**

These experiments examined the ganglionic effects of high doses of chlorisondamine using changes in heart rate and blood pressure as measures of ganglionic blockade. Blood pressure and heart rate were compared among several doses of chlorisondamine and mecamylamine to evaluate the de-

---

**Fig. 3.** Effect of chlorisondamine and mecamylamine pretreatment on nicotine-induced increases in blood pressure. The peak blood pressure after each dose of nicotine was normalized to the saline baseline and compared among pretreatment groups. A, 0.1 mg/kg chlorisondamine with 30-min and 24-h pretreatment. B, 1 mg/kg chlorisondamine with 30-min and 24-h pretreatment. C, 10 mg/kg chlorisondamine with 30-min, 24-h, and 3-day pretreatment. D, 1 mg/kg mecamylamine with 30 min and 10 mg/kg mecamylamine with 24-h pretreatment. Data were analyzed using two-way ANOVA with Bonferroni’s post tests, \( * \), \( p < 0.05 \); \( ** \), \( p < 0.01 \); and \( *** \), \( p < 0.001 \).
gree of ganglionic blockade. The duration of chlorisondamine’s ganglionic blockade was assessed by administering chlorisondamine or mecamylamine either 30 min, 24 h, or 3 days before nicotinic-induced stimulation of blood pressure and heart rate.

There are intense effects associated with 10 mg/kg, but not 1 mg/kg, chlorisondamine in the pigeon; these include increased breathing, loss of balance, and prostration (our unpublished data). These effects are not likely to be due to changes in blood pressure because 1 and 10 mg/kg chlorisondamine lowered blood pressure to a similar extent. Only the high dose of chlorisondamine (10 mg/kg) raised heart rate for 90 min; however, the increase in heart rate is unlikely to account for the physiological effects observed because it diminished before the onset of the other effects. Chlorisondamine is reported to cause decreases in blood pressure among several species regardless of route of administration: humans (100 mg, oral) (Grimson et al., 1955); monkeys (0.32–5 mg/kg i.v.) (Tella et al., 1993); dogs (0.1–3 mg/kg i.v.) (Maxwell et al., 1956); rabbits (0.32 mg/kg i.v.) (Maxwell et al., 1958); and rats (2.5–5 mg/kg i.v. or i.a.) (Abdel-Rahman, 1989; Kiritsy-Roy et al., 1990, Tella et al., 1992, Houdi et al., 1995; Suntajuliana et al., 1996). In the current study, the depressor effect of chlorisondamine reached its maximum at 1 mg/kg, but the peak change in heart rate occurred after 10 mg/kg chlorisondamine.

Control of heart rate is particularly complex, readily susceptible to both direct and reflex actions. This may explain the observation that the effects of chlorisondamine on heart rate were more variable than on blood pressure. Chlorisondamine produced dose-dependent effects, lowering (0.1 mg/kg), having no effect (1 mg/kg), or raising (10 mg/kg) heart rate. In other species, chlorisondamine has been found to both lower and raise heart rate. Chlorisondamine raised heart rate in dogs (0.32–2 mg/kg i.v.) (Maxwell et al., 1956, 1958), but in rats and monkeys, 1 to 5 mg/kg chlorisondamine caused a decrease in heart rate with i.v. or i.a. administration (Abdel-Rahman, 1989, Tella et al., 1992, 1993; and Suntajuliana et al., 1996). Chlorisondamine (10 mg/kg) may cause a more complete and/or persistent ganglionic blockade than lower doses of chlorisondamine or mecamylamine, blocking all autonomic signals after a decrease in blood pressure. This would explain a large reflex increase in heart rate, which was not observed with only a partial or short-lived ganglionic blockade caused by the lower doses of chlorisondamine or mecamylamine.

In the pigeon, control of heart rate is likely to be partly centrally mediated because chlorisondamine only blocked nicotine-induced tachycardia after administration 3 days prior (Fig. 4C), a time point when chlorisondamine blocks nicotinic effects on behavior (Chadman and Woods, 2001) but has no effect on blood pressure (Fig. 3C). Chlorisondamine is not expected to have access to the central nicotinic receptors at early time points due to its charged nature. Chlorisondamine did not attenuate the nicotine-induced tachycardia at 30-min pretreatment, in contrast to mecamylamine. Therefore, in this study the changes in heart rate seem to be due to both reflex action after lowered blood pressure and control from the central nervous system. Mecamylamine has ready access to both central and peripheral nicotinic receptors and causes only a decrease in heart rate regardless of dose, reflecting action at both central and peripheral nicotinic receptors.

The persistence of the central blockade by chlorisondamine is its most unusual feature. Therefore, another question for this study was to evaluate the length of the ganglionic blockade by chlorisondamine. Chlorisondamine (10 mg/kg) blocks nicotinic effects on behavior in the pigeon for up to 4 days (Chadman and Woods, 2001). This dose of chlorisondamine blocked the nicotine-induced increase in blood pressure at both 30 min and 24 h, which diminished by 3 days. The duration of the ganglionic blockade by 10 mg/kg chlorisond-
damine is longer-lasting than the blockade by mecamylamine in the pigeon but not as long as the central blockade.

The acute observable effects of 10 mg/kg chlorisondamine are more profound than those produced by 1 mg/kg chlorisondamine (our unpublished data). The lower dose of chlorisondamine also produces a blockade of nicotine-induced physiological effects for up to 48 h and nicotine-induced decreases in rate of food-reinforced pecking for 24 h (Chadman and Woods, 2001). This is not as long-lasting as 10 mg/kg chlorisondamine but may be better tolerated. The decrease in blood pressure by these two doses of chlorisondamine is similar, but only 10 mg/kg causes a significant increase in heart rate. The two doses of chlorisondamine blocked the pressor and tachycardic effects of nicotine to a similar extent, but the blockade by 1 mg/kg is much shorter. Thus, 1 mg/kg chlorisondamine produced central nicotinic blockade of long duration but with fewer cardiovascular effects than 10 mg/kg chlorisondamine.

The observable physiological effects associated with 10 mg/kg chlorisondamine in the pigeon are more prominent than those associated with 1 mg/kg. However, 10 mg/kg chlorisondamine does not seem to produce a larger degree of ganglionic blockade than 1 mg/kg, as measured by blood pressure. It may be that blood pressure cannot be lowered beyond that of 1 mg/kg chlorisondamine so that any larger degree blockade by 10 mg/kg chlorisondamine was not able to be detected. Therefore, it will be useful to use other measures of ganglionic blockade, such as mydriasis or ptosis, to evaluate the large dose of chlorisondamine.

Acknowledgments

We thank Liz Diller and Anita Amin for technical assistance and Dr. John Traynor (Department of Pharmacology, University of Michigan) for comments on the manuscript.

References


Address correspondence to: James H. Woods, 1301 MSRB III, 1150 W. Medical Center Dr., Ann Arbor, MI 48109-0632. E-mail: jhwoods@umich.edu